Creaven P J
Bull Cancer. 1979;66(1):85-8.
The value of pharmacokinetic parameters of antitumor agents to predict for response to chemotherapy of patients with cancer is unknown. Factors which would lead to an expectuation that they would be of value in this regard are the requirement that cells be exposed to a minimum concentration of drug for a minimum period of time to produce cell kill and with certain agents the further requirement that this exposure be during a specific critical phase of the cell cycle. The potential limitations of these parameters for response prediction include the fact that they are whole body parameters which do not distinguish between targets for drug response and targets for dose limiting drug toxicity and that the way drugs are usually given clinically is such as to minimize the effect of patient variation in these parameters. Some practical limitations of their use are the need for very sensitive assays for their accurate definition, the need for computer analysis and the dependence of parameter estimates on the use of the correct model. It is concluded that by themselves pharmacokinetic parameters are unlikely to be of predictive value when drugs are used optimally in a clinical setting, but when considered with biochemical and other parameters may contribute to overall response prediction.
抗肿瘤药物的药代动力学参数对于预测癌症患者化疗反应的价值尚不清楚。导致人们预期它们在这方面具有价值的因素包括:细胞要暴露于最低浓度的药物下至少一段时间才能产生细胞杀伤,对于某些药物还有进一步的要求,即这种暴露要发生在细胞周期的特定关键阶段。这些参数用于反应预测的潜在局限性包括:它们是全身参数,无法区分药物反应靶点和剂量限制药物毒性靶点,而且临床上通常给予药物的方式会尽量减少患者这些参数变化的影响。其使用的一些实际局限性包括:需要非常灵敏的检测方法来准确定义它们,需要计算机分析,以及参数估计依赖于正确模型的使用。结论是,在临床环境中最佳使用药物时,药代动力学参数本身不太可能具有预测价值,但与生化及其他参数一起考虑时,可能有助于总体反应预测。